Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) Critical Contrast

Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for Xilio Therapeutics and Janone, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	0	0	1	0	3.00
Janone	0	0	0	0	0.00

Xilio Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 409.10%. Given Xilio Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Janone.

Institutional & Insider Ownership

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 6.3% of Janone shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by company insiders. Comparatively, 4.9% of Janone shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Xilio Therapeutics and Janone’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	N/A	-211.50%	-80.31%
Janone	N/A	-2,940.01%	-39.81%

Volatility and Risk

Xilio Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, Janone has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.

Earnings & Valuation

This table compares Xilio Therapeutics and Janone”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$6.34 million	6.41	-$76.40 million	($1.28)	-0.61
Janone	$7.11 million	9.72	-$7.81 million	N/A	N/A

Janone has higher revenue and earnings than Xilio Therapeutics.

Summary

Xilio Therapeutics beats Janone on 6 of the 11 factors compared between the two stocks.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

About Janone

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.